All In Biotech

Drug Trial Radar · NCT07192666

Exosomes in Patients With Ocular Involvement of Sjögren's Syndrome

Exploratory Clinical Trial of Exosomes in Patients With Ocular Involvement of Sjögren's Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-center, multiple-dosing, prospective, nonrandom, single-arm trial.

Conditions

  • Sjögren's Syndrome

Interventions

  • Exosome PreparationDrug

    Each subject will have a single designated study eye; this eye will receive multiple instillations-one drop four times daily for 14 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: from subjects receiving administration to Day 29 post-administration

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.